The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors – an overview and update

Author:

Attygalle Ayoma D.1,Chan John K. C.2,Coupland Sarah E.34,Du Ming-Qing5,Ferry Judith A.6,Jong Daphne de7,Gratzinger Dita8ORCID,Lim Megan S.9,Naresh Kikkeri N.10,Nicolae Alina11,Ott German12,Rosenwald Andreas13,Schuh Anna14,Siebert Reiner15

Affiliation:

1. Department of Histopathology, The Royal Marsden Hospital, London, UK

2. Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong, SAR China

3. Department of Molecular and Clinical Cancer Medicine, ISMIB, University of Liverpool, Liverpool, UK

4. Liverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, UK

5. Department of Pathology, University of Cambridge, Cambridge, UK

6. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

7. The Netherlands Cancer Institute, Amsterdam, The Netherlands

8. Department of Pathology, Stanford University School of Medicine, Stanford, USA

9. Memorial Sloan Kettering Cancer Center, New York City, NY, USA

10. Fred Hutchinson Cancer Center, University of Washington, Seattle, USA

11. Department of Pathology, University Hospital of Strasbourg, Strasbourg, France

12. Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

13. Institute of Pathology, Julius-Maximilians-UniversitätWürzburg, and Cancer Center Mainfranken, Würzburg, Germany

14. Department of Oncology, University of Oxford, Oxford, UK

15. Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Reference131 articles.

1. Swerdlow SH Campo E Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: Revised 4th edition. 2017.

2. Swerdlow SH Campo E Harris NL et al. World health organization classification of tumours of haematopoietic and lymphoid tissues. 2008.

3. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

4. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

5. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3